文献速递浆细胞疾病

中国AL型淀粉样变性多中心真实世界研究:诊断、治疗与预后

A Multicenter National Study of AL Amyloidosis in China: Insights Into Real-World Diagnosis, Treatment, and Prognosis.
PubMed 文献 · Am J Hematol · 2026-06-23

这项中国多中心回顾性研究分析了2008至2025年1070例新诊断系统性轻链(AL)型淀粉样变性患者,发现年诊断量增加且2024年起一线治疗从蛋白酶体抑制剂(PI)方案显著转向达雷妥尤单抗方案。达雷妥尤单抗诱导的血液学缓解更深更快,早期死亡率在1、3、6个月分别为5.5%、13.2%、16.2%。

要点

  • 达雷妥尤单抗一线治疗较PI方案显著提高≥HemVGPR率(80.3% vs 70.8%)并缩短起效时间(1.2 vs 1.8个月)。
  • 6个月死亡率16.2%,达雷妥尤单抗是6个月死亡的独立保护因素。
  • 合并肝脏和心脏受累者预后差,中位EFS 12.8个月、OS 51.0个月。

核心结论

  • 达雷妥尤单抗一线治疗在中国AL型淀粉样变性真实世界中疗效优于PI方案。
  • 血液学深度缓解(HemCR及以上)与更好EFS和OS相关,MRD阴性进一步改善HemCR患者EFS。

研究设计与样本

  • 全国多中心回顾性研究,纳入2008-2025年新诊断系统性AL型淀粉样变性患者1070例。

主要发现

  • 达雷妥尤单抗方案vs PI方案:≥HemVGPR率80.3% vs 70.8%(p=0.012),中位起效时间1.2 vs 1.8个月(p=0.001)。
  • 心脏总体缓解率63.1% vs 53.3%(p=0.030)。
  • 1、3、6个月早期死亡率分别为5.5%、13.2%、16.2%。
  • 中位EFS为44.4个月,中位OS未达到。
  • 合并肝脏和心脏受累者中位EFS 12.8个月、OS 51.0个月。

关键数值与推荐

  • 多因素分析显示ECOG PS>2、肝脏受累和gain1q是EFS的不良预后因素,≥HemVGPR为保护因素。
  • OS独立危险因素包括肝脏受累、合并多发性骨髓瘤和ECOG PS>2,≥HemVGPR和心脏缓解预测生存改善。
  • 达雷妥尤单抗是6个月死亡的独立保护因素。

临床怎么用

  • 中国AL型淀粉样变性一线治疗可优先考虑达雷妥尤单抗方案以获得更快更深血液学缓解。
  • 应早期识别肝脏和心脏受累等高危亚组并加强监测。
  • 治疗中追求血液学完全缓解及MRD阴性以改善长期生存。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

This national, multicenter, retrospective study analyzed 1070 patients with newly diagnosed systemic light-chain (AL) amyloidosis in China (2008-2025). Findings reveal increasing annual diagnoses and a marked shift in first-line therapy from proteasome inhibitor (PI)-based regimens to predominantly daratumumab-based regimens since 2024. Monthly kinetic assessments demonstrated that daratumumab-based induction produced deeper and faster hematologic responses than PI-based therapy [≥ very good hematologic partial response (HemVGPR): 80.3% vs. 70.8%, p = 0.012; median time to ≥ HemVGPR: 1.2 vs. 1.8 months, p = 0.001], with significantly superior cardiac overall response (63.1% vs. 53.3%, p = 0.030). Early mortality rates at 1, 3, and 6 months were 5.5%, 13.2%, and 16.2%, respectively, with daratumumab-based therapy identified as an independent protective factor for 6-month mortality. Median event-free survival (EFS) was 44.4 months, while median overall survival (OS) was not reached. Achievement of hematologic complete response (HemCR) conferred superior EFS and OS over HemVGPR (both p < 0.001), with minimal residual disease negativity further improving EFS in HemCR patients (p = 0.043). Concurrent hepatic and cardiac involvement defined a high-risk subgroup with poor outcomes (median EFS 12.8 months, OS 51.0 months). Multivariable analysis confirmed Eastern Cooperative Oncology Group (ECOG) performance status (PS) > 2, liver involvement, and gain1q as adverse prognostic factors for EFS, whereas ≥ HemVGPR was protective. For OS, liver involvement, concomitant multiple myeloma, and ECOG PS > 2 were independent risk factors, while ≥ HemVGPR and cardiac response predicted improved survival. This study establishes a contemporary benchmark for AL amyloidosis management in China, confirming the superior real-world efficacy of daratumumab-based frontline therapy.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Li J, Yu C, Wang J, et al. A Multicenter National Study of AL Amyloidosis in China: Insights Into Real-World Diagnosis, Treatment, and Prognosis. Am J Hematol. 2026. PMID: 42333973. doi:10.1002/ajh.70418

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。